soul trial oral semaglutide cardiovascular outcomes 2025 results 2024 nejm Oral Semaglutide's Impact on Cardiovascular Events in Type 2 Diabetes Patients with Cardiovascular and Kidney Disease: SOUL Trial Results Novo Nordisk reports SOUL trial

Notably, DHHC9 and GLUT1 are highly expressed in GBM cells compared with non-transformed normal human astrocytes (NHAs) (Supplementary Fig

You inject into the subcutaneous fat layer of the stomach area, not into muscle

The most common first-time medication was semaglutide (n = 644,272)

J Natl Cancer Inst 1997

A.TriantafyllouG.DincerF.FilippaiosA.KoB.-J.et al

How PlexusDx Supports a More Personalized Approach PlexusDx genetic insights may help provide context around individual peptide pathway function, which can support more informed conversations with your healthcare provider about treatment selection and dosing strategy